Gefitinib-loaded Starch Nanoparticles for Battling Lung Cancer: Optimization by Full Factorial Design and Cytotoxicity Evaluation

Overview

Journal Saudi Pharm J

Specialty Pharmacy

Date 2023 Jan 23

PMID 36685309

Authors

Haitham Amin

Shaaban K Osman

Ahmed M Mohammed

Gamal Zayed

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the number one killer among all cancer types. For decades, clinicians have been using conventional chemotherapeutics, but they can't rely on them alone anymore, because they poison bad cells and good cells as well. Researchers exploited nanotechnology as a potential tool to develop a platform for drug delivery to improve therapeutic efficiency. A quality by design synthesis of gefitinib-loaded starch nanoparticles (Gef-StNPs) has emerged as an essential tool to study and optimize the factors included in their synthesis. Therefore, we applied design of experiment (DOE) tools to attain the essential knowledge for the synthesis of high-quality Gef-StNPs that can deliver and concentrate the gefitinib (Gef) at A549 cells, thereby improving therapeutic efficacy and minimizing adverse effects. The cytotoxicity after exposing the A549 human lung cancer cells to the optimized Gef-StNPs was found to be much higher than that of the pure Gef (IC = 6.037 ± 0.24 and 21.65 ± 0.32 μg/mL, respectively). The optimized Gef-StNPs formula showed superiority over the pure Gef regarding the cellular uptake in A549 human cell line (3.976 ± 0.14 and 1.777 ± 0.1 μg/mL) and apoptotic population (77.14 ± 1.43 and 29.38 ± 1.11 %), respectively. The results elucidate why researchers have a voracious appetite for using natural biopolymers to combat lung cancer and paint an optimistic picture of their potential to be a promising tool in battling lung cancer.

Citing Articles

A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.

Eker F, Duman H, Akdasci E, Bolat E, Saritas S, Karav S Molecules. 2024; 29(15).

PMID: 39124888 PMC: 11314082. DOI: 10.3390/molecules29153482.

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer.

Adekiya T, Moore M, Thomas M, Lake G, Hudson T, Adesina S Pharmaceutics. 2024; 16(1).

PMID: 38258124 PMC: 10819281. DOI: 10.3390/pharmaceutics16010114.

Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches.

Aryal S, Park S, Park H, Park C, Kim W, Thakur D Int J Nanomedicine. 2023; 18:7865-7888.

PMID: 38146467 PMC: 10749572. DOI: 10.2147/IJN.S432839.

Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells.

Aljuffali I, Anwer M, Ahmed M, Alalaiwe A, Aldawsari M, Fatima F Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004415 PMC: 10674849. DOI: 10.3390/ph16111549.

References

Wang K, Purushotham S, Lee J, Na M, Park H, Oh S . In vivo imaging of tumor apoptosis using histone H1-targeting peptide. J Control Release. 2010; 148(3):283-91. DOI: 10.1016/j.jconrel.2010.09.010. View

Dong X, Liu L, Wang Y, Li T, Wu Z, Yuan H . The compatibilization of poly (propylene carbonate)/poly (lactic acid) blends in presence of core-shell starch nanoparticles. Carbohydr Polym. 2020; 254:117321. DOI: 10.1016/j.carbpol.2020.117321. View

Phillip Lee Y, Sathigari S, Jean Lin Y, Ravis W, Chadha G, Parsons D . Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm. 2009; 35(9):1113-20. DOI: 10.1080/03639040902783074. View

Bade B, Dela Cruz C . Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020; 41(1):1-24. DOI: 10.1016/j.ccm.2019.10.001. View

Wolfram J, Ferrari M . Clinical Cancer Nanomedicine. Nano Today. 2019; 25:85-98. PMC: 6662733. DOI: 10.1016/j.nantod.2019.02.005. View

Gidwani B, Vyas A, Kaur C . Investigation of inclusion behaviour of gefitinib with epichlorohydrin-β-cyclodextrin polymer: preparation of binary complex, stoichiometric determination and characterization. J Pharm Biomed Anal. 2018; 160:31-37. DOI: 10.1016/j.jpba.2018.07.025. View

Martins J, das Neves J, Fuente M, Celia C, Florindo H, Gunday-Tureli N . The solid progress of nanomedicine. Drug Deliv Transl Res. 2020; 10(3):726-729. PMC: 7228908. DOI: 10.1007/s13346-020-00743-2. View

Xia W, Zheng B, Li T, Lian F, Lin Y, Liu R . Fabrication, characterization and evaluation of myricetin adsorption onto starch nanoparticles. Carbohydr Polym. 2020; 250:116848. DOI: 10.1016/j.carbpol.2020.116848. View

Anand U, Dey A, Chandel A, Sanyal R, Mishra A, Pandey D . Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023; 10(4):1367-1401. PMC: 10310991. DOI: 10.1016/j.gendis.2022.02.007. View

10.

Lopez-Silva M, Agama-Acevedo E, Bello-Perez L, Alvarez-Ramirez J . Influence of gelatinization degree and octenyl succinic anhydride esterification on the water sorption characteristics of corn starch. Carbohydr Polym. 2021; 270:118378. DOI: 10.1016/j.carbpol.2021.118378. View

11.

Garizo A, Castro F, Martins C, Almeida A, Dias T, Fernardes F . p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. J Control Release. 2021; 337:329-342. DOI: 10.1016/j.jconrel.2021.07.035. View

12.

Alshetaili A . Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines. Saudi J Biol Sci. 2021; 28(9):5065-5073. PMC: 8381081. DOI: 10.1016/j.sjbs.2021.05.025. View

13.

Aghda N, Dabbaghianamiri M, Tunnell J, Betancourt T . Design of smart nanomedicines for effective cancer treatment. Int J Pharm. 2022; 621:121791. DOI: 10.1016/j.ijpharm.2022.121791. View

14.

Duyen T, Van Hung P . Morphology, crystalline structure and digestibility of debranched starch nanoparticles varying in average degree of polymerization and fabrication methods. Carbohydr Polym. 2021; 256:117424. DOI: 10.1016/j.carbpol.2020.117424. View

15.

Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

16.

Kim J, Kim J, Park E, Kim J . Starch nanoparticles resulting from combination of dry heating under mildly acidic conditions and homogenization. Carbohydr Polym. 2017; 168:70-78. DOI: 10.1016/j.carbpol.2017.03.061. View

17.

El-Naggar M, El-Rafie M, El-sheikh M, El-Feky G, Hebeish A . Synthesis, characterization, release kinetics and toxicity profile of drug-loaded starch nanoparticles. Int J Biol Macromol. 2015; 81:718-29. DOI: 10.1016/j.ijbiomac.2015.09.005. View

18.

El-Sheikh M . New technique in starch nanoparticles synthesis. Carbohydr Polym. 2017; 176:214-219. DOI: 10.1016/j.carbpol.2017.08.033. View

19.

Markowicz-Piasecka M, Huttunen J, Sikora J, Huttunen K . Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines. Bioorg Chem. 2019; 87:321-334. DOI: 10.1016/j.bioorg.2019.03.036. View

20.

Xia W, He D, Fu Y, Wei X, Liu H, Ye J . Advanced technology for nanostarches preparation by high speed jet and its mechanism analysis. Carbohydr Polym. 2017; 176:127-134. DOI: 10.1016/j.carbpol.2017.08.072. View